Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

Peer Review reports

Original Submission
5 May 2018	Submitted	Original manuscript
5 Jul 2018	Reviewed	Reviewer Report - Joung Jang
17 Sep 2018	Reviewed	Reviewer Report - Junji Furuse
17 Oct 2018	Reviewed	Reviewer Report - Masashi Kanai
29 Nov 2018	Author responded	Author comments - Markus Moehler
Resubmission - Version 2
29 Nov 2018	Submitted	Manuscript version 2
6 Dec 2018	Reviewed	Reviewer Report - Masashi Kanai
12 Dec 2018	Author responded	Author comments - Markus Moehler
Resubmission - Version 3
12 Dec 2018	Submitted	Manuscript version 3
Publishing
13 Dec 2018	Editorially accepted
11 Jan 2019	Article published	10.1186/s12885-018-5223-7

Back to article page